查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1197405

左心耳市场增长、趋势、COVID-19 影响和预测 (2023-2028)

Left Atrial Appendage Devices Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 117 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在预测期内，全球左心耳市场的复合年增长率预计为 20.1%。

主要亮点

  • COVID-19 的爆发对市场增长产生了前所未有的影响。 疫情导致各种心臟手术推迟或取消，影响了对左心耳的需求。 例如，欧洲 PMC 于 2021 年 7 月发表的一篇研究论文报告称，2020 年 4 月至 2020 年 8 月期间在印度进行的心臟手术减少了 73%。 心臟手术的下降对市场增长产生了轻微的负面影响。 但是，由于封锁的放鬆，这些推迟的手术已经进行。
  • 此外，COVID-19 还影响了人们的心臟健康，增加了对左心耳的需求。 由于这些因素，预计未来五年市场将继续增长。
  • 市场增长的主要驱动力是老年人口的增加以及随之而来的心血管疾病的增加。 此外，预计全球人口中房颤患病率的增加也将有助于市场增长。
  • 例如，根据美国国家生物技术信息中心 (NCBI) 的数据，2021 年 2 月全球房颤患病率为 375.74 亿例（占世界人口的 0.51%），与过去 20 年相比也有所增加减少 33% 至 预计全球人口中心房颤动情况的增加将推动预测期内研究市场的增长。
  • 65 岁以上的老年人患心房颤动等心血管疾病的风险也会增加，这会进一步导致心肌梗塞。 根据联合国经济和社会事务部（UDESA）的一份报告，到 2022 年，世界 65 岁及以上人口的比例预计将从 2022 年的 10% 上升到 2050 年的 16%。 因此，预计在预测期内，全球易患心血管疾病的老年人口增加将推动市场增长。
  • 此外，增加产品开发预计将有助于所研究市场的增长。 例如，2022 年 6 月，Conformal Medical Inc. 宣布招募其 CLAAS 系统的 CONFORM 关键试验的第一名参与者。 第一批患者在美国的两个地点登记。 CLAAS 系统旨在封闭非瓣膜性心房颤动 (Afib) 患者的左心耳 (LAA)，并在不使用抗凝剂的情况下降低中风风险。 Conformal Medical 表示，调查设备豁免 (IDE) 试验的结果将有助于该设备获得美国食品和药物管理局 (FDA) 的上市前批准。
  • 因此，房颤患病率上升和创新产品开发预计将促进市场增长。 然而，设备的高成本可能会在预测期内抑制市场增长。

左心耳市场趋势

预计在预测期内，左心耳附件市场将由医院部门主导

  • 左心耳市场的医院部分预计将出现显着增长。 医院数量的增加和基础设施的进步，以及心房颤动等心血管疾病发病率的增加，预计将推动对左心耳的需求，并有助于研究领域的增长。
  • 此外，预计心房颤动负担的增加将对这一细分市场产生重大影响。 根据 NCBI，房颤是最常见的心律失常。 随着世界老龄化，房颤预计到 2050 年将影响美国的 6-1200 万人，到 2060 年将影响欧洲的 1790 万人。 2021 年 5 月发表的另一篇 NCBI 论文指出，北美、欧洲、中国和东南亚的房颤年龄和性别标准化患病率最高。
  • 还介绍说，房颤在中等收入国家的发病率是低收入国家的 7 倍，在高收入国家的发病率是低收入国家的 11 倍。 如此高的心房颤动和各种心血管疾病患病率也有望在预测期内推动研究领域的增长。
  • 此外，预计医院数量的增加也将促进所研究细分市场的增长。 例如，美国医院协会（AHA）2022年发布的统计数据显示，2022年美国活跃医院总数为6093家，入□□院人数为33356853人次。 因此，大量医院推动了对左心耳的需求增加，从而推动了研究领域的增长。
  • 因此，医院数量的增加和对晚期左心耳的需求增加等因素预计将增加该细分市场对左心耳的需求，从而推动该细分市场的增长。 .

预计北美将占据很大的市场份额，预计在预测期内也会如此

  • 由于心房颤动病例不断增加，预计北美将成为左心附件市场的重要区域。 此外，由于技术的快速引入，主要市场参与者的出现和先进产品的推出也有望促进市场的增长。
  • 根据美国疾病控制与预防中心 (CDC) 的数据（2022 年 10 月），到 2030 年，美国预计将有 1210 万人患有房颤。 2021 年 7 月发布的一项类似的 NCBI 分析发现，墨西哥 8,686 名患者中有 498 名患有心房颤动，男性和老年女性的患病率更高。 此外，随着老年人口的增加，未来研究目标市场的需求有望扩大。 左心房附件管理至关重要，因为心房颤动很可能导致心肌梗塞。 此外，新技术正在被引入市场，增加了这些设备的采用。
  • 此外，预计老龄化人口的增加将推动北美国家/地区的市场增长。 例如，根据加拿大统计局 2022 年 8 月发布的数据，加拿大 70-74 岁的人口有 1,847,585 人，而 80-84 岁的人口为 840,545 人。 预计易患此类心血管疾病的老龄化人口增加将推动对左心耳的需求并促进市场增长。
  • 该国主要参与者的存在、技术进步和有利的产品批准将促进美国研究市场的增长。 例如，2021 年 8 月，雅培（Abbott）公司的左心房附件封闭 Amplatzer Amulet 获得 FDA 批准，用于治疗有缺血性中风风险的心房颤动。 该设备可立即关闭心房颤动患者的左心耳（血栓形成部位），从而降低中风风险并消除对抗凝血剂的直接需求。
  • 因此，心血管疾病负担增加、老年人口增加、主要市场参与者的存在以及产品开发等因素预计将促进该地区的市场增长。

左心耳市场的竞争对手分析

由于多家公司在全球和区域运营，左心耳市场在本质上是分散的。 预计将主导左心耳市场的主要公司包括 Abbott、Articure、Boston Scientific、Johnson and Johnson、Lifetech Scientific、Occlutech、Cardia Inc。

其他福利。

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动因素
    • 心房颤动的负担增加
    • 设备的技术进步
  • 市场製约因素
    • 设备成本高
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模：单位：百万美元）

  • 按产品分类
    • 心内膜
    • 心外膜
  • 最终用户
    • 医院
    • 门诊手术中心
    • 其他最终用户
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 世界其他地区

第六章竞争格局

  • 公司简介
    • Abbott
    • Articure
    • Boston Scientific
    • Johnson & Johnson（Biosense Webster）
    • Lifetech Scientific
    • Occlutech
    • Cardia Inc
    • Aegis Medical Group
    • Acutus Medical Inc
    • ONOCOR Llc

第7章 市场机会今后动向

简介目录
Product Code: 70653

The global left atrial appendage devices market is expected to register a CAGR of 20.1% during the forecast period.

Key Highlights

  • The COVID-19 outbreak had an unprecedented impact on the growth of the market. This outbreak resulted in the postponement and cancellation of various cardiac surgeries, affecting the demand for left atrial appendage devices. For instance, a research article published by Europe PMC in July 2021 reported a 73% decrease in cardiac procedures performed in India between April and August 2020. Such reduction in cardiac procedures had a slight negative impact on the market's growth. However, with the relaxation of the lockdown, these postponed surgeries were carried out.
  • Additionally, COVID -19 has also impacted people's cardiac health, increasing the demand for left atrial appendage devices. Thus, owing to these factors, the studied market is expected to continue its growth over the coming five years.
  • The key contributors to the market growth are the increasing geriatric population and associated cardiovascular diseases. Also, the rise in atrial fibrillation among the global population is expected to contribute to the market's growth.
  • For example, according to the National Center for Biotechnology Information (NCBI), in February 2021, the worldwide prevalence of atrial fibrillation was 37,574 million cases (0.51% of the world's population), which also increased by 33% during the last 20 years. Such an increase in atrial fibrillation conditions among the global population is expected to drive the growth of the studied market during the forecast period.
  • Moreover, people aged 65 years and above are at a higher threat of causing cardiovascular diseases such as atrial fibrillation, which might further lead to heart stroke. According to the UN Department of Economic and Social Affairs (UDESA) report, 2022, the share of the global population aged 65 years or above is projected to rise from 10% in 2022 to 16% in 2050. Thus, the increase in the global geriatric population prone to cardiovascular diseases is expected to drive the market's growth during the forecast period.
  • Furthermore, increasing product developments are expected to contribute to the growth of the studied market. For instance, in June 2022, Conformal Medical Inc. announced the enrolment of the first participants in the CONFORM pivotal trial of its CLAAS System. The first patients were enrolled at two sites in the US. The CLAAS System has been designed to seal the left atrial appendage (LAA) in non-valvular atrial fibrillation (Afib) patients to reduce stroke risk without using anticoagulants. Conformal Medical noted that the findings from the investigational device exemption (IDE) study will help the company seek pre-market approval for the device from the US Food and Drug Administration (FDA ).
  • Therefore, the increasing prevalence of atrial fibrillation and innovative product developments are expected to contribute to the market's growth. However, the high cost of devices may restrain the growth of the market during the forecast period.

Left Atrial Appendage Devices Market Trends

Hospital Segment is Expected to Hold a Significant Share in the Left Atrial Appendage Devices Market Over the Forecast Period

  • The hospital segment of the left atrial appendage devices market is expected to show significant growth. The increasing number of hospitals and advancing infrastructure, coupled with the increasing incidence of cardiovascular disorders such as atrial fibrillation, are expected to drive the demand for left atrial appendage devices, thereby contributing to the growth of the studied segment.
  • Furthermore, the increasing burden of atrial fibrillation is expected to be a significant contributor to this segment. According to the NCBI, atrial fibrillation is the most frequent cardiac arrhythmia. As the population ages globally, atrial fibrillation (AF) is predicted to affect 6-12 million people in the USA by 2050 and 17.9 million in Europe by 2060. Also, another NCBI article published in May 2021 mentioned that age and gender-standardized prevalence of atrial fibrillation was highest in North America, Europe, China, and South East Asia.
  • The report also mentioned that compared with low-income countries, atrial fibrillation was 7-fold higher in middle-income countries and 11-fold higher in high-income countries. Such a high prevalence of atrial fibrillation and various cardiovascular disorders is also expected to drive the growth of the studied segment over the forecast period.
  • Additionally, the increasing number of hospitals is also expected to contribute to the growth of the studied segment. For instance, the American Hospital Association (AHA) statistics published in 2022 show that the total number of active hospitals in the United States was 6,093 in 2022, with 33,356,853 hospital admissions. Thus, the high volume of hospitals drives increased demand for left atrial appendage devices, thereby boosting the studied segment growth.
  • Hence, factors such as the increasing number of hospitals and increasing demand for advanced left atrial appendage devices are expected to increase the demand for left atrial appendage devices in this segment and thus drive the market segment's growth.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same Over the Forecast Period

  • North America is expected to be a dominant region in the left atrial appendage devices market owing to the growing number of cases of atrial fibrillation. Additionally, the launch of advanced products with the presence of major market players and quick adoption of the technologies are also expected to contribute to the market's growth.
  • According to Centre for Disease Control and Prevention (CDC) data, October 2022, it is predicted that 12.1 million people in the United States will have atrial fibrillation by the year 2030. According to a similar NCBI analysis released in July 2021, atrial fibrillation was discovered in 498 of the 8,686 patients in the Mexican population, with a higher prevalence in men and older women. Also, with the rising geriatric population, the demand for the studied market is expected to grow in the future. Atrial fibrillation is likely to cause heart stroke, so left atrial appendage management is of utmost importance. Furthermore, novel technologies are being introduced in the market, increasing the adoption of these devices.
  • Additionally, the rising geriatric population is expected to drive the market's growth in North American countries. For instance, the data published by Statistics Canada in August 2022 indicated that the population aged 70 to 74 years in Canada was 1,847,585, whereas the population aged 80 to 84 years was 840,545. Such a rise in the geriatric population prone to developing cardiovascular diseases is expected to drive the demand for left atrial appendage devices, thereby contributing to the market's growth.
  • The presence of key players in the country, technological advancements, and the availability of favorable product approvals augment the growth of the market studied in the United States. For instance, in August 2021, Abbott received approval from the FDA for its Amplatzer Amulet left atrial appendage occluder to treat the device with atrial fibrillation at risk of ischemic stroke. The device offers immediate closure of the left atrial appendage - an area where blood clots can form in people suffering from atrial fibrillation - reducing their risk of stroke and immediately eliminating the need for blood-thinning medication.
  • Thus, factors such as the increasing burden of cardiovascular disorders, the growing geriatric population, the presence of major market players, and product developments are expected to contribute to the market growth in this region.

Left Atrial Appendage Devices Market Competitor Analysis

The left atrial appendage devices market is fragmented in nature due to the presence of several companies operating globally as well as regionally. Key players that are expected to be dominant in left atrial appendage devices market are Abbott, Articure, Boston Scientific, Johnson and Johnson, Lifetech Scientific, Occlutech, Cardia Inc., among others

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Burden of Atrial Fibrillation
    • 4.2.2 Technological Advancements in the Devices
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Devices
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - in USD Million)

  • 5.1 By Product
    • 5.1.1 Endocardial
    • 5.1.2 Epicardial
  • 5.2 By End User
    • 5.2.1 Hospitals
    • 5.2.2 Ambulatory Surgical Centres
    • 5.2.3 Other End Users
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Rest of the World

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Abbott
    • 6.1.2 Articure
    • 6.1.3 Boston Scientific
    • 6.1.4 Johnson & Johnson (Biosense Webster)
    • 6.1.5 Lifetech Scientific
    • 6.1.6 Occlutech
    • 6.1.7 Cardia Inc
    • 6.1.8 Aegis Medical Group
    • 6.1.9 Acutus Medical Inc
    • 6.1.10 ONOCOR Llc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS